The United States government, through the Biomedical Advanced Research and Development Authority (BARDA), has committed up to $482 million to…
Read More
FDA Proposes Permanent Authorization of Rare Pediatric Disease Priority Review Voucher Program to Foster Regulatory Stability
The United States Food and Drug Administration (FDA) is making a significant move to permanently authorize the rare pediatric disease…
Read More
Everest Medicines Acquires Hasten Biopharmaceuticals for $250 Million to Bolster Asia Pacific Chronic Disease Portfolio and Commercial Reach
Everest Medicines, a leading biopharmaceutical company focused on developing and commercializing innovative medicines for chronic diseases, has announced a significant…
Read More
Halozyme and Vertex sign deal for Hypercon technology
Halozyme Therapeutics, a pioneer in drug delivery technologies, has announced a significant global exclusive partnership and license agreement with Vertex…
Read More
US Imposes 100% Tariff on Branded Pharmaceuticals, Sparking Industry Concerns and Geopolitical Debate
The pharmaceutical industry is bracing for significant disruption following the US administration’s recent decision to implement a 100% tariff on…
Read More
Sidewinder Therapeutics Secures $137 Million in Series B Financing to Advance Bispecific Antibody-Drug Conjugate Pipeline
Sidewinder Therapeutics has announced the successful closure of a substantial $137 million Series B financing round, a significant development signaling…
Read More
RoosterBio and MineBio Forge Exclusive Partnership to Accelerate MSC and Exosome Therapies in China
RoosterBio, a prominent innovator in the field of mesenchymal stem cell (MSC) and exosome bioprocessing, has announced an exclusive distributor…
Read More
The Hyper-Connected Hospital: Bridging the Gap Between Digital Ambition and Network Readiness
The healthcare landscape is undergoing a profound metamorphosis, transforming hospitals into hyper-connected environments where artificial intelligence applications, remote patient monitoring,…
Read More
US Import Tariffs Fail to Deter Biopharma Giants as European Contract Manufacturing Surges for FDA-Approved Drugs
The biopharmaceutical industry is demonstrating a significant and counterintuitive trend in 2025, with companies increasingly channeling investments into European-based contract…
Read More
Gilead Acquires Antibody-Drug Conjugate Pioneer Tubulis for Up to $5 Billion, Bolstering Oncology Pipeline
Sixteen months after forging a strategic collaboration, Gilead Sciences has announced its definitive agreement to acquire German biotechnology firm Tubulis,…
Read More
